Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC

BACKGROUND: Targeted therapies offer novel opportunities to explore biomarkers based on their mode of action. Taking this into consideration, we evaluated six angiogenesis-related proteins as potential predictive biomarkers, which expression might predict the benefit of bevacizumab treatment in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianconi, Daniela, Herac, Merima, Posch, Florian, Schmeidl, Margit, Unseld, Matthias, Kieler, Markus, Brettner, Robert, Müllauer, Leonhard, Riedl, Jakob, Gerger, Armin, Scheithauer, Werner, Prager, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446555/
https://www.ncbi.nlm.nih.gov/pubmed/32922518
http://dx.doi.org/10.1177/1758835920928635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446555/
https://www.ncbi.nlm.nih.gov/pubmed/32922518
http://dx.doi.org/10.1177/1758835920928635

Ejemplares similares